

Giulio Marchesini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8333779/publications.pdf>

Version: 2024-02-01

417
papers

56,626
citations

3933

88
h-index

1190

228
g-index

427
all docs

427
docs citations

427
times ranked

41976
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002â€“2033: the ITA.LI.CA database. <i>Gut</i> , 2023, 72, 141-152.	12.1	57
2	Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients. <i>Transplantation</i> , 2022, 106, 462-478.	1.0	13
3	Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 149-153.	1.8	0
4	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
5	The Role of Psychological Well-Being in Weight Loss: New Insights from a Comprehensive Lifestyle Intervention. <i>International Journal of Clinical and Health Psychology</i> , 2022, 22, 100279.	5.1	5
6	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. <i>Lancet</i> , The, 2022, 399, 61-116.	13.7	257
7	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1-16.	2.6	15
8	Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). <i>Digestive and Liver Disease</i> , 2022, 54, 170-182.	0.9	12
9	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780.	3.7	114
10	Prognostic Value of Stress Hyperglycemia in Patients Admitted to Medical/Geriatric Departments for Acute Medical Illness. <i>Diabetes Therapy</i> , 2022, 13, 145-159.	2.5	5
11	A psycho-educational intervention for the prevention of foot lesions in people with diabetes: Report of a clinical audit. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, , .	2.6	1
12	Non-alcoholic fatty liver disease: Not time for an obituary just yet!. <i>Journal of Hepatology</i> , 2021, 74, 972-974.	3.7	24
13	Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A realâ€“world data analysis. <i>Liver International</i> , 2021, 41, 731-742.	3.9	27
14	European â€œNAFLD Preparedness Indexâ€™ â€“ Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234.	4.9	27
15	Incidence of diabetes mellitus in Italy in year 2018. A nationwide population-based study of the ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2338-2344.	2.6	8
16	Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. <i>Nutrients</i> , 2021, 13, 2748.	4.1	28
17	Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2661-2668.	2.6	5
18	Genes and lifestyle: Which of the two is more relevant in driving NAFLD progression?. <i>Digestive and Liver Disease</i> , 2021, 53, 1433-1434.	0.9	1

#	ARTICLE	IF	CITATIONS
19	The Effect of Neuropathy and Diabetes Type on Multisegment Foot Kinematics: A Cohort Study on 70 Participants with Diabetes. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 8848.	2.5	2
20	Non-alcoholic fatty liver disease: A patient guideline. <i>JHEP Reports</i> , 2021, 3, 100322.	4.9	109
21	Management of non-alcoholic fatty liver disease. <i>BMJ, The</i> , 2021, 372, m4747.	6.0	99
22	Analysis of Clinical Profiles, Deformities, and Plantar Pressure Patterns in Diabetic Foot Syndrome. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 11464.	2.5	1
23	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. <i>Acta Diabetologica</i> , 2020, 57, 71-80.	2.5	18
24	The association between weight maintenance and session-by-session diet adherence, weight loss and weight-loss satisfaction. <i>Eating and Weight Disorders</i> , 2020, 25, 127-133.	2.5	16
25	Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.	4.4	102
26	A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24.	3.7	123
27	Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation. <i>Hepatology</i> , 2020, 71, 1213-1227.	7.3	209
28	Signal of potentially protective drug-drug interactions from spontaneous reporting systems: proceed with caution. <i>Acta Diabetologica</i> , 2020, 57, 115-116.	2.5	4
29	A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1945-1953.	2.6	17
30	The Effect of Liraglutide on Î²-Blockade for Preventing Variceal Bleeding: A Case Series. <i>Annals of Internal Medicine</i> , 2020, 173, 404-405.	3.9	13
31	Stress Hyperglycemia and Mortality in Subjects With Diabetes and Sepsis. , 2020, 2, e0152.		34
32	Clinical burden of diabetes in Italy in 2018: a look at a systemic disease from the ARNO Diabetes Observatory. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001191.	2.8	17
33	Correlations between weight-bearing 3D bone architecture and dynamic plantar pressure measurements in the diabetic foot. <i>Journal of Foot and Ankle Research</i> , 2020, 13, 64.	1.9	9
34	Motivational Interviewing Adapted to Group Setting for the Treatment of Relapse in the Behavioral Therapy of Obesity. A Clinical Audit. <i>Nutrients</i> , 2020, 12, 3881.	4.1	3
35	Maternal PKU: Defining phenylalanine tolerance and its variation during pregnancy, according to genetic background. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 977-983.	2.6	3
36	Prevalence of orthorexic traits in type 2 diabetes mellitus: at the crossroads between nutritional counseling and eating disorders. <i>Acta Diabetologica</i> , 2020, 57, 1117-1119.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1014-1022.	2.6	24
38	Nurse-managed basal-bolus versus sliding-scale insulin regimen in subjects with hyperglycemia at admission for orthopedic surgery: a propensity score approach. Acta Diabetologica, 2020, 57, 835-842.	2.5	11
39	Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Review of Gastroenterology and Hepatology, 2020, 14, 127-135.	3.0	17
40	<p>Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery</p><p>. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 9-17.	2.4	21
41	Lifestyle Changes for the Treatment of Nonalcoholic Fatty Liver Disease - A 2015-19 Update. Current Pharmaceutical Design, 2020, 26, 1110-1118.	1.9	9
42	Obesity and NAFLD: Same Problem?. , 2020, , 1-14.		0
43	Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations. Nutrition, Metabolism and Cardiovascular Diseases, 2019, 29, 983-990.	2.6	12
44	Adipose tissue-associated cancer risk: Is it the fat around the liver, or the fat inside the liver?. Journal of Hepatology, 2019, 71, 1073-1075.	3.7	9
45	Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study. Endocrinology, Diabetes and Metabolism, 2019, 2, e00082.	2.4	8
46	Effect of Short Term Intensive Lifestyle Intervention on Hepatic Steatosis Indexes in Adults with Obesity and/or Type 2 Diabetes. Journal of Clinical Medicine, 2019, 8, 851.	2.4	17
47	Referral pathways for NAFLD fibrosis in primary care – No longer a “needle in a haystack”. Journal of Hepatology, 2019, 71, 246-248.	3.7	11
48	Prevention and Treatment of Sarcopenic Obesity in Women. Nutrients, 2019, 11, 1302.	4.1	57
49	Body composition, dual-energy X-ray absorptiometry and obesity: the paradigm of fat (re)distribution. BJR case Reports, 2019, 5, 20170078.	0.2	4
50	Dapagliflozin and cardiovascular outcomes: anything else to DECLARE?. Expert Opinion on Pharmacotherapy, 2019, 20, 1087-1090.	1.8	4
51	Moderate Alcohol Intake in Non-Alcoholic Fatty Liver Disease: To Drink or Not to Drink?. Nutrients, 2019, 11, 3048.	4.1	29
52	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
53	Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation, 2019, 103, 22-27.	1.0	296
54	Type 2 diabetes treatment and progression of chronic kidney disease in Italian family practice. Journal of Endocrinological Investigation, 2019, 42, 787-796.	3.3	2

#	ARTICLE	IF	CITATIONS
55	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease, 2019, 51, 190-205.	0.9	77
56	Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients. Nutrition, 2019, 61, 143-150.	2.4	13
57	Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis. Acta Diabetologica, 2019, 56, 289-299.	2.5	13
58	Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases. Proceedings of the IEEE, 2018, 106, 723-737.	21.3	34
59	Expected benefits and motivation to weight loss in relation to treatment outcomes in group-based cognitive-behavior therapy of obesity. Eating and Weight Disorders, 2018, 23, 205-214.	2.5	16
60	The Economic Burden of Insulin-Related Hypoglycemia in Adults with Diabetes: An Analysis from the Perspective of the Italian Healthcare System. Diabetes Therapy, 2018, 9, 1037-1047.	2.5	10
61	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 533-542.	2.6	83
62	DXA-assessed changes in body composition in obese women following two different weight loss programs. Nutrition, 2018, 46, 13-19.	2.4	9
63	Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name..... Journal of Hepatology, 2018, 68, 391-392.	3.7	20
64	Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control. Journal of Endocrinological Investigation, 2018, 41, 307-314.	3.3	16
65	The Effect of Lutein on Eye and Extra-Eye Health. Nutrients, 2018, 10, 1321.	4.1	142
66	An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers. Journal of Hepatology, 2018, 69, 1155-1163.	3.7	80
67	Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2018, 19, 1903-1914.	1.8	18
68	Statins in liver disease: not only prevention of cardiovascular events. Expert Review of Gastroenterology and Hepatology, 2018, 12, 743-744.	3.0	5
69	Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?. Diabetes, Obesity and Metabolism, 2018, 20, 2711-2723.	4.4	18
70	Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. Cardiovascular Diabetology, 2018, 17, 28.	6.8	43
71	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
72	Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. , 2018, 68, 349.		1

#	ARTICLE	IF	CITATIONS
73	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. Digestive and Liver Disease, 2017, 49, 471-483.	0.9	254
74	3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet, The, 2017, 389, 1399-1409.	13.7	502
75	Acute Heart Failure in the Emergency Department: the SAFE-SIMEU Epidemiological Study. Journal of Emergency Medicine, 2017, 53, 178-185.	0.7	1
76	Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment. Diabetes, Obesity and Metabolism, 2017, 19, 1594-1601.	4.4	18
77	Branched-chain amino acids for people with hepatic encephalopathy. The Cochrane Library, 2017, 5, CD001939.	2.8	136
78	Coffee and tea breaks for liver health. Journal of Hepatology, 2017, 67, 221-223.	3.7	10
79	Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 510-518.	3.7	169
80	Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease?. Digestive and Liver Disease, 2017, 49, 235-240.	0.9	35
81	Long-term treatment of severe obesity: are lifestyle interventions still an option?. Expert Review of Endocrinology and Metabolism, 2017, 12, 391-400.	2.4	14
82	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 887-897.	11.4	231
83	Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1098-1107.	2.6	31
84	Response to: Comment to "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". Journal of Hepatology, 2017, 66, 466-467.	3.7	40
85	The Influence of Weight-Loss Expectations on Weight Loss and of Weight-Loss Satisfaction on Weight Maintenance in Severe Obesity. Journal of the Academy of Nutrition and Dietetics, 2017, 117, 32-38.	0.8	26
86	Does the liver accelerate ageing: Talking muscles and liver?. Journal of Hepatology, 2017, 66, 8-10.	3.7	2
87	Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program. Internal and Emergency Medicine, 2017, 12, 45-52.	2.0	11
88	Estimating the risk of severe hypoglycemic event related to glucose-lowering treatment among Italian patients with diabetes: the HYPOTHESIS database. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 711-720.	1.9	3
89	Evidence-Based Medicine and the Problem of Healthy Volunteers. Annals of Hepatology, 2017, 16, 832-834.	1.5	6
90	Long-term weight loss maintenance for obesity: a multidisciplinary approach. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2016, 9, 37.	2.4	177

#	ARTICLE	IF	CITATIONS
91	The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease. <i>Medicine (United States)</i> , 2016, 95, e3446.	1.0	44
92	How Much Fat Does One Need to Eat to Get a Fatty Liver? A Dietary View of NAFLD. , 2016, , 109-122.		1
93	The relative burden of diabetes complications on healthcare costs: The population-based CINECA-SID ARNO Diabetes Observatory. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 944-950.	2.6	44
94	Response to letter to the editor: Gallo F etÂal., âœœThe economic burden ofÂsevere hypoglycemia: Two sides of the same coinâ€• <i>Nutr Metab Cardiovasc Dis.</i> 2016;26:850â€“851.. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 851-852.	2.6	0
95	EASLâ€“EASDâ€“EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2016, 64, 1388-1402.	3.7	3,403
96	Costs associated with emergency care and hospitalization for severe hypoglycemia. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 345-351.	2.6	49
97	EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease. <i>Obesity Facts</i> , 2016, 9, 65-90.	3.4	371
98	Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 380-386.	2.6	30
99	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. <i>Diabetes and Metabolism</i> , 2016, 42, 142-156.	2.9	78
100	NAFLD-Associated Hepatocellular Carcinoma: a Threat to Patients with Metabolic Disorders. <i>Current Hepatology Reports</i> , 2016, 15, 103-112.	0.9	3
101	Incidence, prevalence, costs and quality of care of type 1 diabetes in Italy, age 0â€“29 years: The population-based CINECA-SID ARNO Observatory, 2002â€“2012. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 1104-1111.	2.6	14
102	Switching among Equivalents in Chronic Cardiovascular Therapies: â€œReal Worldâ€™ Data from Italy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 118, 63-69.	2.5	1
103	Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with <scp>NAFLD</scp> using the <scp>SAF</scp> score as histological reference. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 877-889.	3.7	70
104	Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction. <i>Digestive Diseases</i> , 2016, 34, 3-10.	1.9	29
105	When the journey from obesity to cirrhosis takes an early start. <i>Journal of Hepatology</i> , 2016, 65, 249-251.	3.7	8
106	Are severe hypoglycemic episodes in diabetes correctly identified by administrative data? Evidence of underreporting from the HYPOTHESIS study. <i>Acta Diabetologica</i> , 2016, 53, 677-680.	2.5	7
107	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 323-334.	27.0	2,809
108	Diet, weight loss, and liver health in nonalcoholic fatty liver disease: Pathophysiology, evidence, and practice. <i>Hepatology</i> , 2016, 63, 2032-2043.	7.3	239

#	ARTICLE	IF	CITATIONS
109	Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women. Journal of Sexual Medicine, 2016, 13, 46-54.	0.6	17
110	Time for Glucagon like peptide-1 receptor agonists treatment for patients with NAFLD?. Journal of Hepatology, 2016, 64, 262-264.	3.7	30
111	Acute heart failure in the emergency department: a follow-up study. Internal and Emergency Medicine, 2016, 11, 115-122.	2.0	5
112	ÂNASH: A glance at the landscape of pharmacological treatment. Annals of Hepatology, 2016, 15, 673-81.	1.5	23
113	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		29
114	Weight Loss Expectations and Attrition in Treatment-Seeking Obese Women. Obesity Facts, 2015, 8, 311-318.	3.4	34
115	Branched-chain amino acids for people with hepatic encephalopathy. , 2015, , CD001939.		44
116	Personality, attrition and weight loss in treatment seeking women with obesity. Clinical Obesity, 2015, 5, 266-272.	2.0	12
117	Evidence of a diurnal thermogenic handicap in obesity. Chronobiology International, 2015, 32, 299-302.	2.0	17
118	The Hepatic Expression of Vitamin D Receptor Is Inversely Associated With the Severity of Liver Damage in Genotype 1 Chronic Hepatitis C Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 193-200.	3.6	28
119	Visceral Fat and Body Composition Changes in a Female Population After RYGBP: a Two-Year Follow-Up by DXA. Obesity Surgery, 2015, 25, 443-451.	2.1	49
120	Weight Loss for a Healthy Liver. Gastroenterology, 2015, 149, 274-278.	1.3	11
121	NAFLD incidence and remission: Only a matter of weight gain and weight loss?. Journal of Hepatology, 2015, 62, 15-17.	3.7	84
122	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015, 373, 2117-2128.	27.0	8,841
123	Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Digestive and Liver Disease, 2015, 47, 181-190.	0.9	551
124	Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. Journal of Hepatology, 2015, 62, 928-933.	3.7	162
125	Obesity in the Context of Aging: Quality of Life Considerations. Pharmacoeconomics, 2015, 33, 655-672.	3.3	31
126	ICD Code Retrieval: Novel Approach for Assisted Disease Classification. Lecture Notes in Computer Science, 2015, , 147-161.	1.3	8

#	ARTICLE	IF	CITATIONS
127	Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?. World Journal of Gastroenterology, 2014, 20, 10128.	3.3	27
128	Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1346-1353.	2.6	39
129	Sexuality and Psychopathological Aspects in Premenopausal Women with Metabolic Syndrome. Journal of Sexual Medicine, 2014, 11, 2020-2028.	0.6	21
130	Reply to: "Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients". Journal of Hepatology, 2014, 60, 677-678.	3.7	1
131	A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. Nutrition, 2014, 30, 696-701.	2.4	51
132	The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease, 2014, 18, 73-89.	2.1	27
133	Stage of change and motivation to healthy diet and habitual physical activity in type 2 diabetes. Acta Diabetologica, 2014, 51, 559-566.	2.5	35
134	Personality Traits in Obesity Associated with Binge Eating and/or Night Eating. Current Obesity Reports, 2014, 3, 120-126.	8.4	9
135	The influence of cognitive factors in the treatment of obesity: Lessons from the QUOVADIS study. Behaviour Research and Therapy, 2014, 63, 157-161.	3.1	37
136	A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity. Diabetology and Metabolic Syndrome, 2014, 6, 74.	2.7	28
137	Liver in the analysis of body composition by dual-energy X-ray absorptiometry. British Journal of Radiology, 2014, 87, 20140232.	2.2	7
138	Reply to: "Is industrial fructose just a marker of an unhealthy dietary pattern?". Journal of Hepatology, 2014, 61, 173-175.	3.7	0
139	Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool. Clinical Nutrition, 2014, 33, 1087-1094.	5.0	9
140	Under-treatment of migrants with diabetes in a universalistic health care system: The ARNO Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 393-399.	2.6	28
141	Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis, 2014, 232, 99-109.	0.8	113
142	The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 1181-1188.	2.6	33
143	Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e87523.	2.5	112
144	Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence?. Metabolic Brain Disease, 2013, 28, 221-225.	2.9	88

#	ARTICLE	IF	CITATIONS
145	Insulin resistance: mechanism and implications for carcinogenesis and hepatocellular carcinoma in NASH. <i>Hepatology International</i> , 2013, 7, 814-822.	4.2	6
146	Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients. <i>Journal of Hepatology</i> , 2013, 59, 1169-1176.	3.7	33
147	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. <i>Acta Diabetologica</i> , 2013, 50, 569-577.	2.5	101
148	A psychological support program for individuals with Type 1 diabetes. <i>Acta Diabetologica</i> , 2013, 50, 209-216.	2.5	18
149	Personality features of obese women in relation to binge eating and night eating. <i>Psychiatry Research</i> , 2013, 207, 86-91.	3.3	27
150	Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2013, 58, 771-777.	3.7	74
151	Emotionally focused group therapy and dietary counseling in binge eating disorder. Effect on eating disorder psychopathology and quality of life. <i>Appetite</i> , 2013, 71, 361-368.	3.7	21
152	Oral Branched-Chain Amino Acids Have a Beneficial Effect on Manifestations of Hepatic Encephalopathy in a Systematic Review with Meta-Analyses of Randomized Controlled Trials. <i>Journal of Nutrition</i> , 2013, 143, 1263-1268.	2.9	92
153	Health and ageing: A cross-sectional study of body composition. <i>Clinical Nutrition</i> , 2013, 32, 569-578.	5.0	64
154	Review article: the diagnosis of non-alcoholic fatty liver disease – availability and accuracy of non-invasive methods. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 392-400.	3.7	156
155	High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 174-182.	2.0	15
156	Physical activity for the prevention and treatment of metabolic disorders. <i>Internal and Emergency Medicine</i> , 2013, 8, 655-666.	2.0	41
157	Elevated 1-Hour Postload Plasma Glucose Levels Identify Subjects With Normal Glucose Tolerance but Impaired β -Cell Function, Insulin Resistance, and Worse Cardiovascular Risk Profile: The GENFIEV Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2100-2105.	3.6	92
158	Longstanding underweight eating disorder: Associated features and treatment outcome. <i>Psychotherapy Research</i> , 2013, 23, 315-323.	1.8	15
159	Preliminary study about the possible glycemic clinical advantage in using a fixed combination of <i>Berberis aristata</i> and <i>Silybum marianum</i> standardized extracts versus only <i>Berberis aristata</i> in patients with type 2 diabetes. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 167.	1.2	44
160	Emotion-Focused Therapy and Dietary Counseling for Obese Patients with Binge Eating Disorder: A Propensity Score-Adjusted Study. <i>Psychotherapy and Psychosomatics</i> , 2013, 82, 193-194.	8.8	18
161	Gender Difference in Hepatic Steatosis Index and Lipid Accumulation Product Ability to Predict Incident Metabolic Syndrome in the Historical Cohort of the Brisighella Heart Study. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 412-416.	1.3	25
162	A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. <i>Obesity</i> , 2013, 21, 1774-1781.	3.0	35

#	ARTICLE	IF	CITATIONS
163	Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study. <i>Critical Care</i> , 2013, 17, R53.	5.8	62
164	Major factors for facilitating change in behavioral strategies to reduce obesity. <i>Psychology Research and Behavior Management</i> , 2013, 6, 101.	2.8	62
165	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089.	2.5	59
166	Quality of Diabetes Care in Italy: Information From a Large Population-Based Multiregional Observatory (ARNO Diabetes). <i>Diabetes Care</i> , 2012, 35, e64-e64.	8.6	17
167	A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity. <i>Pediatric Obesity</i> , 2012, 7, 436-445.	2.8	25
168	Hepatic Encephalopathy and Health-Related Quality of Life. <i>Clinics in Liver Disease</i> , 2012, 16, 159-170.	2.1	29
169	Author's reply: Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 289-290.	1.8	0
170	Impatto delle incretine sulla gestione del paziente diabetico: dati del monitoraggio antidiabetici AIFA. <i>L Endocrinologo</i> , 2012, 13, 210-215.	0.0	0
171	Predicting unfavorable outcome in subjects with diagnosis of chest pain of undifferentiated origin. <i>American Journal of Emergency Medicine</i> , 2012, 30, 61-67.	1.6	3
172	Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones. <i>Drug Safety</i> , 2012, 35, 315-323.	3.2	34
173	Pathogenetic Mechanisms and Cardiovascular Risk. <i>Diabetes Care</i> , 2012, 35, 2607-2612.	8.6	36
174	Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012, 5, 213.	2.4	74
175	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	7.3	113
176	Diabetes and hepatocellular cancer risk: Not only a matter of hyperglycemia. <i>Hepatology</i> , 2012, 55, 1298-1300.	7.3	18
177	Prevalence of Sexual Dysfunction Among Postmenopausal Women with and Without Metabolic Syndrome. <i>Journal of Sexual Medicine</i> , 2012, 9, 434-441.	0.6	59
178	Objective and subjective binge eating in underweight eating disorders: Associated features and treatment outcome. <i>International Journal of Eating Disorders</i> , 2012, 45, 370-376.	4.0	19
179	Gallstone Disease Is Associated with More Severe Liver Damage in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2012, 7, e41183.	2.5	51
180	Anthropometry and Nutritional Rehabilitation in Underweight Eating Disorders. , 2012, , 2807-2820.		0

#	ARTICLE	IF	CITATIONS
181	Night eating syndrome and weight loss outcome in obese patients. International Journal of Eating Disorders, 2011, 44, 150-156.	4.0	25
182	Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome. Expert Opinion on Pharmacotherapy, 2011, 12, 2657-2672.	1.8	20
183	Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting. Diabetes Care, 2011, 34, 1369-1371.	8.6	215
184	Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, 73-77.	0.9	14
185	High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis. Digestive and Liver Disease, 2011, 43, 404-410.	0.9	27
186	Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity. Journal of Hepatology, 2011, 54, 1244-1249.	3.7	107
187	The Direct Economic Cost of Pharmacologically-Treated Diabetes in Italy-2006. The ARNO Observatory. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 339-346.	2.6	36
188	Metabolic syndrome in subjects at high risk for type 2 diabetes: The genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. Nutrition, Metabolism and Cardiovascular Diseases, 2011, 21, 699-705.	2.6	16
189	Cognitive-Behavioral Strategies to Increase the Adherence to Exercise in the Management of Obesity. Journal of Obesity, 2011, 2011, 1-11.	2.7	156
190	TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. Journal of Viral Hepatitis, 2011, 18, e372-80.	2.0	20
191	Cognitive-Behavioral Treatment of Nonalcoholic Fatty Liver Disease: A Propensity Score-Adjusted Observational Study. Obesity, 2011, 19, 763-770.	3.0	44
192	Effects of Cognitive-Behavioral Treatment for Weight Loss in Family Members. Journal of the American Dietetic Association, 2011, 111, 1712-1719.	1.1	23
193	HBV and HCV infection in type 2 diabetes mellitus: a survey in three diabetes units in different Italian areas. Acta Diabetologica, 2011, 48, 337-343.	2.5	22
194	Massive Weight Loss Without Surgery in a Super Obese Patient. Obesity Surgery, 2011, 21, 540-545.	2.1	4
195	Therapeutic hypothermia after cardiac arrest: The Mediterranean-diet Italian style. Resuscitation, 2011, 82, 637-638.	3.0	1
196	Treatment of non-alcoholic fatty liver disease with focus on emerging drugs. Expert Opinion on Emerging Drugs, 2011, 16, 121-136.	2.4	18
197	Analysis of Different Decision Aids for Clinical Use in Pediatric Head Injury in an Emergency Department of a General Hospital. Journal of Trauma, 2011, 70, E79-E83.	2.3	6
198	Venesection for non-alcoholic fatty liver disease unresponsive to lifestyle counselling--a propensity score-adjusted observational study. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 141-149.	0.5	64

#	ARTICLE	IF	CITATIONS
199	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes—the lower, the better?. International Journal of Epidemiology, 2011, 40, 1539-1541.	1.9	9
200	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut, 2011, 60, 108-115.	12.1	30
201	Symptoms of Starvation in Eating Disorder Patients. , 2011, , 2259-2269.		7
202	Behavioral Aspects of Nonalcoholic Fatty Liver Disease: Diet, Causes, and Treatment. , 2011, , 1833-1844.		0
203	Metabolic Syndrome and Insulin Resistance in Subjects with Morbid Obesity. Obesity Surgery, 2010, 20, 295-301.	2.1	31
204	Effects of cognitive-behavioral therapy on Eating Disorders: Neurotransmitter secretory response to treatment. Psychoneuroendocrinology, 2010, 35, 729-737.	2.7	10
205	The changing face of mild head injury: Temporal trends and patterns in adolescents and adults from 1997 to 2008. Injury, 2010, 41, 913-917.	1.7	17
206	Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 2010, 51, 1158-1167.	7.3	371
207	Clinical and psychological correlates of health-related quality of life in obese patients. Health and Quality of Life Outcomes, 2010, 8, 90.	2.4	72
208	Predicting intracranial lesions by antiplatelet agents in subjects with mild head injury. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1275-1279.	1.9	36
209	Double Heterozygous Mutations Involving Both <i>HNF1A</i> /MODY3 and <i>HNF4A</i> /MODY1 Genes. Diabetes Care, 2010, 33, 2336-2338.	8.6	22
210	Metabolic syndrome: relevant for all types of chronic liver diseases?. Gut, 2010, 59, 1314-1315.	12.1	1
211	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	12.1	148
212	The Effect of Lifestyle Changes in Non-Alcoholic Fatty Liver Disease. Digestive Diseases, 2010, 28, 267-273.	1.9	55
213	Insulin Resistance in Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2010, 16, 1941-1951.	1.9	321
214	Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 272-282.	0.9	202
215	Prevention and treatment of nonalcoholic fatty liver disease. Digestive and Liver Disease, 2010, 42, 331-340.	0.9	18
216	HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2010, 138, 905-912.	1.3	246

#	ARTICLE	IF	CITATIONS
217	Weight management, psychological distress and binge eating in obesity. A reappraisal of the problem. <i>Appetite</i> , 2010, 54, 269-273.	3.7	33
218	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2010, 3, 373.	2.4	62
219	Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. <i>World Journal of Gastroenterology</i> , 2010, 16, 348.	3.3	35
220	Disease and comorbidity effects on quality of life. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 504-506.	17.8	6
221	ESPEN Guidelines on Parenteral Nutrition: Hepatology. <i>Clinical Nutrition</i> , 2009, 28, 436-444.	5.0	222
222	Psychological Variables Associated with Weight Loss in Obese Patients Seeking Treatment at Medical Centers. <i>Journal of the American Dietetic Association</i> , 2009, 109, 2010-2016.	1.1	70
223	Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. <i>Hepatology</i> , 2009, 49, 195-203.	7.3	65
224	Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. <i>Hepatology</i> , 2009, 50, 697-706.	7.3	140
225	Predictors of health-related quality of life in patients with chronic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 469-476.	3.7	140
226	Night eating syndrome in class II obesity: metabolic and psychopathological features. <i>International Journal of Obesity</i> , 2009, 33, 899-904.	3.4	48
227	Self-induced vomiting in eating disorders: Associated features and treatment outcome. <i>Behaviour Research and Therapy</i> , 2009, 47, 680-684.	3.1	25
228	Endothelial function and its relationship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients: a pilot study. <i>Fertility and Sterility</i> , 2009, 91, 2537-2544.	1.0	37
229	Are behavioural approaches feasible and effective in the treatment of type 2 diabetes? A propensity score analysis vs. prescriptive diet. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2009, 19, 313-320.	2.6	20
230	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-639.	1.0	22
231	Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. <i>Hepatology</i> , 2008, 47, 746-754.	7.3	204
232	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. <i>Diabetologia</i> , 2008, 51, 1947-1953.	6.3	374
233	Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. <i>Liver Transplantation</i> , 2008, 14, 1648-1654.	2.4	242
234	Underweight eating disorder without overevaluation of shape and weight: Atypical anorexia nervosa?. <i>International Journal of Eating Disorders</i> , 2008, 41, 705-712.	4.0	45

#	ARTICLE	IF	CITATIONS
235	Retinolâ€binding protein 4: A new marker of virusâ€induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology, 2008, 48, 28-37.	7.3	55
236	Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology, 2008, 48, 792-798.	7.3	600
237	Metabolic syndrome, psychological status and quality of life in obesity: the QUOVADIS Study. International Journal of Obesity, 2008, 32, 185-191.	3.4	69
238	Metabolic Syndrome and Health-Related Quality of Life: Does Psychological Well-Being Matter?. Annals of Epidemiology, 2008, 18, 592-593.	1.9	3
239	Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 624-631.	2.6	67
240	Personality dimensions and treatment drop-outs among eating disorder patients treated with cognitive behavior therapy. Psychiatry Research, 2008, 158, 381-388.	3.3	22
241	Is amenorrhea a clinically useful criterion for the diagnosis of anorexia nervosa?. Behaviour Research and Therapy, 2008, 46, 1290-1294.	3.1	36
242	Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study. Clinical Therapeutics, 2008, 30, 1168-1176.	2.5	119
243	Compulsive exercise to control shape or weight in eating disorders: prevalence, associated features, and treatment outcome. Comprehensive Psychiatry, 2008, 49, 346-352.	3.1	300
244	Nutritional treatment of chronic liver failure. Hepatology Research, 2008, 38, S93-S101.	3.4	22
245	Prevalence of elevated liver enzymes in Type 2 diabetes mellitus and its association with the metabolic syndrome. Journal of Endocrinological Investigation, 2008, 31, 146-152.	3.3	55
246	Vascular Risk in Young Women With Polycystic Ovary and Polycystic Ovary Syndrome. Obstetrics and Gynecology, 2008, 111, 385-395.	2.4	46
247	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. American Journal of Gastroenterology, 2008, 103, 1136-1144.	0.4	170
248	Hepatotoxicity of fast food?. Gut, 2008, 57, 568-570.	12.1	23
249	Obesity-Associated Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2008, 93, s74-s80.	3.6	260
250	Which Treatment for Nonalcoholic Fatty Liver Disease?. Mini-Reviews in Medicinal Chemistry, 2008, 8, 767-775.	2.4	9
251	Intrauterine Growth Retardation, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in Children. Diabetes Care, 2007, 30, 2638-2640.	8.6	123
252	Iron Depletion by Phlebotomy Improves Insulin Resistance in Patients With Nonalcoholic Fatty Liver Disease and Hyperferritinemia: Evidence from a Case-Control Study. American Journal of Gastroenterology, 2007, 102, 1251-1258.	0.4	274

#	ARTICLE	IF	CITATIONS
253	Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease. Gut, 2007, 56, 1296-1301.	12.1	66
254	Correspondence Between the International Diabetes Federation Criteria for Metabolic Syndrome and Insulin Resistance in a Cohort of Italian Nondiabetic Caucasians: The GISIR database. Diabetes Care, 2007, 30, e33-e33.	8.6	4
255	Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 493-498.	2.6	16
256	Diabetes and liver disease: An ominous association. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 63-70.	2.6	112
257	Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 684-698.	2.6	63
258	The effect of inpatient cognitive-behavioral therapy for eating disorders on temperament and character. Behaviour Research and Therapy, 2007, 45, 1335-1344.	3.1	34
259	Steatosi epatica non alcolica: un aspetto emergente della sindrome metabolica. L Endocrinologo, 2007, 8, 136-143.	0.0	0
260	Metabolic Syndrome and NASH. Clinics in Liver Disease, 2007, 11, 105-117.	2.1	119
261	Essential hypertension and chronic viral hepatitis. Digestive and Liver Disease, 2007, 39, 466-472.	0.9	5
262	Effect of Euglycemic Insulin Infusion on Plasma Levels of Branched-Chain Amino Acids in Cirrhosis. Hepatology, 2007, 3, 184-187.	7.3	33
263	The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology, 2007, 45, 846-854.	7.3	2,448
264	The Effect of Obesity Management on Body Image in Patients Seeking Treatment at Medical Centers. Obesity, 2007, 15, 2320-2327.	3.0	35
265	Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. British Journal of Clinical Pharmacology, 2007, 63, 346-355.	2.4	30
266	The treatment of hepatic encephalopathy. Metabolic Brain Disease, 2007, 22, 389-405.	2.9	65
267	NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Current Diabetes Reports, 2007, 7, 175-180.	4.2	56
268	Psychological Distress in Morbid Obesity in Relation to Weight History. Obesity Surgery, 2007, 17, 391-399.	2.1	57
269	Effects of Physical Exercise on the Quality of Life of Individuals with Diabetes and Obesity. , 2007, , 191-201.		0
270	An empowerment-based educational program improves psychological well-being and health-related quality of life in Type 1 diabetes. Journal of Endocrinological Investigation, 2006, 29, 405-412.	3.3	27

#	ARTICLE	IF	CITATIONS
271	Construct Validity of the Short Form€36 Health Survey and Its Relationship with BMI in Obese Outpatients. Obesity, 2006, 14, 1429-1437.	3.0	44
272	Monitoring intervention programmes for out-of-hospital cardiac arrest in a mixed urban and rural setting. Resuscitation, 2006, 71, 180-187.	3.0	32
273	Outcome research in obesity: lessons from the QUOVADIS study. Drug Development Research, 2006, 67, 260-270.	2.9	1
274	Reply:. Hepatology, 2006, 43, 1168-1169.	7.3	18
275	Gender, fatty liver and GGT. Hepatology, 2006, 44, 278-279.	7.3	49
276	Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology, 2006, 44, 1648-1655.	7.3	137
277	A physical activity program to reinforce weight maintenance following a behavior program in overweight/obese subjects. International Journal of Obesity, 2006, 30, 697-703.	3.4	33
278	Complexity of attrition in the treatment of obesity: clues from a structured telephone interview. International Journal of Obesity, 2006, 30, 1132-1137.	3.4	93
279	Disease Management of the Metabolic Syndrome in a Community: Study Design and Process Analysis on Baseline Data. Metabolic Syndrome and Related Disorders, 2006, 4, 7-16.	1.3	10
280	Non-alcoholic fatty liver disease (NAFLD) - A novel common aspect of the metabolic syndrome. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2006, 150, 101-104.	0.6	22
281	Nonalcoholic fatty liver disease and the metabolic syndrome. Current Opinion in Lipidology, 2005, 16, 421-427.	2.7	309
282	Branched-Chain Amino Acid Supplementation in Patients with Liver Diseases. Journal of Nutrition, 2005, 135, 1596S-1601S.	2.9	68
283	Update on branched-chain amino acid supplementation in liver diseases. Current Opinion in Gastroenterology, 2005, 21, 197-200.	2.3	31
284	Update on nutritional supplementation with branched-chain amino acids. Current Opinion in Clinical Nutrition and Metabolic Care, 2005, 8, 83-87.	2.5	37
285	A Positive Blood Alcohol Concentration Is the Main Predictor of Recurrent Motor Vehicle Crash. Annals of Emergency Medicine, 2005, 46, 161-167.	0.6	25
286	Continuous care in the treatment of obesity: an observational multicentre study. Journal of Internal Medicine, 2005, 258, 265-273.	6.0	71
287	Weight Loss Expectations in Obese Patients and Treatment Attrition: An Observational Multicenter Study. Obesity, 2005, 13, 1961-1969.	4.0	246
288	Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study. Hepatology, 2005, 42, 44-52.	7.3	1,118

#	ARTICLE	IF	CITATIONS
289	Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2005, 42, 473-480.	7.3	554
290	Insulin resistance: A metabolic pathway to chronic liver disease. <i>Hepatology</i> , 2005, 42, 987-1000.	7.3	730
291	Clinical Performance of NICE Recommendations versus NCWFNS Proposal in Patients with Mild Head Injury. <i>Journal of Neurotrauma</i> , 2005, 22, 1419-1427.	3.4	47
292	Plasma Adiponectin in Nonalcoholic Fatty Liver Is Related to Hepatic Insulin Resistance and Hepatic Fat Content, Not to Liver Disease Severity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 3498-3504.	3.6	370
293	Is liver disease a threat to patients with metabolic disorders?. <i>Annals of Medicine</i> , 2005, 37, 333-346.	3.8	26
294	Aminotransferase and gamma-glutamyl transpeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 333-339.	3.3	130
295	NAFLD treatment: Cognitive-behavioral therapy has entered the arena. <i>Journal of Hepatology</i> , 2005, 43, 926-928.	3.7	24
296	Diabetes prevention strategy in offspring of type 2 diabetic patients with a direct involvement of the diseased parents. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2005, 15, 237-238.	2.6	5
297	Psychological status and depression in patients with liver cirrhosis. <i>Digestive and Liver Disease</i> , 2005, 37, 593-600.	0.9	154
298	A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease. <i>American Journal of Gastroenterology</i> , 2005, 100, 1082-1090.	0.4	631
299	Eating behavior affects quality of life in type 2 diabetes mellitus. <i>Eating and Weight Disorders</i> , 2005, 10, 251-257.	2.5	19
300	A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department. <i>Emergency Medicine Journal</i> , 2004, 21, 317-322.	1.0	10
301	WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , 2004, 21, 383-387.	2.3	129
302	Nutritional therapy in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S401-S405.	2.8	0
303	Hepatic steatosis in obese patients: clinical aspects and prognostic significance. <i>Obesity Reviews</i> , 2004, 5, 27-42.	6.5	263
304	Weight cycling in treatment-seeking obese persons: data from the QUOVADIS study. <i>International Journal of Obesity</i> , 2004, 28, 1456-1462.	3.4	54
305	Weight Loss Expectations in Obese Patients Seeking Treatment at Medical Centers. <i>Obesity</i> , 2004, 12, 2005-2012.	4.0	63
306	Health-related quality of life in patients with thyroid disorders. <i>Quality of Life Research</i> , 2004, 13, 45-54.	3.1	126

#	ARTICLE	IF	CITATIONS
307	Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. <i>Hepatology</i> , 2004, 39, 179-187.	7.3	394
308	Uric acid levels and liver fibrosis in nonalcoholic fatty liver disease. <i>Hepatology</i> , 2004, 39, 1749-1749.	7.3	7
309	Snoring, hypertension and Type 2 diabetes in obesity. Protection by physical activity. <i>Journal of Endocrinological Investigation</i> , 2004, 27, 150-157.	3.3	35
310	Plasma Ghrelin Concentrations, Food Intake, and Anorexia in Liver Failure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 2136-2141.	3.6	65
311	Non-alcoholic fatty liver and insulin resistance: a cause-effect relationship?. <i>Digestive and Liver Disease</i> , 2004, 36, 165-173.	0.9	76
312	Splanchnic haemodynamics in non-alcoholic fatty liver disease: effect of a dietary/pharmacological treatment. <i>Digestive and Liver Disease</i> , 2004, 36, 406-411.	0.9	40
313	Non-alcoholic steatohepatitis in patients cared in metabolic units. <i>Diabetes Research and Clinical Practice</i> , 2004, 63, 143-151.	2.8	20
314	The metabolic syndrome in treatment-seeking obese persons. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 435-440.	3.4	49
315	Which type of observation for patients with high-risk mild head injury and negative computed tomography?. <i>European Journal of Emergency Medicine</i> , 2004, 11, 65-69.	1.1	16
316	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 1105-1116.	2.4	34
317	Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 1105-1116.	2.4	32
318	Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. <i>Hepatology</i> , 2003, 37, 917-923.	7.3	2,276
319	Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. <i>Gastroenterology</i> , 2003, 124, 1792-1801.	1.3	554
320	Impaired insulin-mediated amino acid plasma disappearance in non-alcoholic fatty liver disease: a feature of insulin resistance. <i>Digestive and Liver Disease</i> , 2003, 35, 722-727.	0.9	16
321	Reduced quality of life of patients with hepatocellular carcinoma. <i>Digestive and Liver Disease</i> , 2003, 35, 46-54.	0.9	48
322	Type 2 Diabetes and the Naaman Syndrome. <i>Diabetes Care</i> , 2003, 26, 3195-3195.	8.6	8
323	Low Ghrelin Concentrations in Nonalcoholic Fatty Liver Disease Are Related to Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5674-5679.	3.6	56
324	Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. <i>Gastroenterology</i> , 2002, 123, 134-140.	1.3	1,332

#	ARTICLE	IF	CITATIONS
325	Effects of long-term oral misoprostol administration on hepatic amino acidâ€“nitrogen metabolism in patients with cirrhosis. <i>Journal of Hepatology</i> , 2002, 37, 15-21.	3.7	1
326	Homocysteine and psychological traits: a study in obesity. <i>Nutrition</i> , 2002, 18, 403-407.	2.4	17
327	Effects of cognitiveâ€“behavioural therapy on health-related quality of life in obese subjects with and without binge eating disorder. <i>International Journal of Obesity</i> , 2002, 26, 1261-1267.	3.4	43
328	NASH: From liver diseases to metabolic disorders and back to clinical hepatology. <i>Hepatology</i> , 2002, 35, 497-499.	7.3	130
329	Factors associated with poor health-related quality of life of patients with cirrhosis. <i>Gastroenterology</i> , 2001, 120, 170-178.	1.3	431
330	Liver inflammatory cells, apoptosis, regeneration and stellate cell activation in non-alcohol steatohepatitis. <i>Digestive and Liver Disease</i> , 2001, 33, 768-777.	0.9	17
331	Systemic prostaglandin E1 infusion and hepatic aminonitrogen to urea nitrogen conversion in patients with type 2 diabetes in poor metabolic control. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 253-258.	3.4	1
332	Metformin in non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2001, 358, 893-894.	13.7	647
333	Nonalcoholic Fatty Liver Disease. <i>Diabetes</i> , 2001, 50, 1844-1850.	0.6	2,100
334	Acquired hepatocerebral degeneration: full recovery after liver transplantation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 136-137.	1.9	45
335	Blood Alcohol Concentration and Management of Road Trauma Patients in the Emergency Department. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 50, 521-528.	2.4	50
336	Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes. <i>Seminars in Liver Disease</i> , 2001, 21, 017-026.	3.6	526
337	Nutritional effects of oral zinc supplementation in cirrhosis. <i>Nutrition Research</i> , 2000, 20, 1079-1089.	2.9	33
338	Synthesis of glutathione in response to methionine load in control subjects and in patients with cirrhosis. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 1434-1439.	3.4	28
339	Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. <i>Digestive and Liver Disease</i> , 2000, 32, 398-405.	0.9	43
340	Total and functional hepatic blood flow decrease in parallel with ageing. <i>Age and Ageing</i> , 1999, 28, 29-33.	1.6	136
341	Prostaglandin E1 infusion and functional hepatic flow in control subjects and in patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 377-384.	2.3	8
342	Cardiovascular disease in cirrhosis A point-prevalence study in relation to glucose tolerance. <i>American Journal of Gastroenterology</i> , 1999, 94, 655-662.	0.4	58

#	ARTICLE	IF	CITATIONS
343	Association of nonalcoholic fatty liver disease with insulin resistance. American Journal of Medicine, 1999, 107, 450-455.	1.5	1,412
344	Effects of Systemic Prostaglandin E1 on Splanchnic and Peripheral Haemodynamics in Control Subjects and in Patients with Cirrhosis. Prostaglandins and Other Lipid Mediators, 1998, 55, 209-218.	1.9	5
345	Effects of systemic prostaglandin e on hepatic amino acid-nitrogen metabolism in patients with cirrhosis. Hepatology, 1998, 27, 815-821.	7.3	10
346	Zinc supplementation improves glucose disposal in patients with cirrhosis. Metabolism: Clinical and Experimental, 1998, 47, 792-798.	3.4	62
347	Quantification of gluconeogenesis in cirrhosis: Response to glucagon. Gastroenterology, 1998, 115, 1530-1540.	1.3	55
348	Gender-dependent alterations in serum leptin in alcoholic cirrhosis. Gastroenterology, 1998, 115, 947-953.	1.3	144
349	LONG-TERM MANAGEMENT OF ALCOHOLIC LIVER DISEASE. Clinics in Liver Disease, 1998, 2, 821-838.	2.1	4
350	Uncertainty in Liver Function Assessment on the Basis of Single-Point Galactose Concentration. Digestion, 1997, 58, 379-383.	2.3	9
351	Glutathione kinetics in normal man and in patients with liver cirrhosis. Journal of Hepatology, 1997, 26, 606-613.	3.7	48
352	Overview of Randomized Clinical Trials of Oral Branched-Chain Amino Acid Treatment in Chronic Hepatic Encephalopathy. Journal of Parenteral and Enteral Nutrition, 1996, 20, 159-164.	2.6	70
353	Transamination of methionine after loading in patients with cirrhosis. Journal of Hepatology, 1996, 24, 95-100.	3.7	9
354	Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. Journal of Hepatology, 1996, 25, 474-480.	3.7	49
355	Transdermal nitroglycerin in cirrhosis. A 24-hour echo-Doppler study of splanchnic hemodynamics. Journal of Hepatology, 1996, 25, 498-503.	3.7	10
356	Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis. Hepatology, 1996, 23, 1084-1092.	7.3	89
357	Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology, 1996, 24, 1047-1052.	7.3	38
358	The course of galactose elimination capacity in patients with alcoholic cirrhosis: Possible use as a surrogate marker for death. Hepatology, 1996, 24, 820-823.	7.3	21
359	Thyroid volume in type 1 diabetes patients without overt thyroid disease. Acta Diabetologica, 1995, 32, 49-52.	2.5	12
360	Effects of beta-blockade on hepatic conversion of amino acid nitrogen and on urea synthesis in cirrhosis. Metabolism: Clinical and Experimental, 1995, 44, 899-905.	3.4	2

#	ARTICLE	IF	CITATIONS
361	Functional hepatic flow and Doppler-assessed total hepatic flow in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1995, 23, 129-134.	3.7	60
362	Prognostic significance of diabetes in patients with cirrhosis. <i>Hepatology</i> , 1994, 20, 119-125.	7.3	161
363	Vegetable and animal protein diets. <i>Journal of Internal Medicine</i> , 1994, 236, 102-103.	6.0	0
364	Hepatic conversion of amino-nitrogen to urea in thyroid diseases. II. A study in hyperthyroid patients. <i>Metabolism: Clinical and Experimental</i> , 1994, 43, 1023-1029.	3.4	7
365	Reduced ubiquinone plasma levels in patients with liver cirrhosis and in chronic alcoholics. <i>Liver</i> , 1994, 14, 138-140.	0.1	20
366	Kinetics of hepatic amino-nitrogen conversion in ageing man. <i>Liver</i> , 1994, 14, 288-294.	0.1	23
367	Prognostic significance of diabetes in patients with cirrhosis*1. <i>Hepatology</i> , 1994, 20, 119-125.	7.3	175
368	Unresponsiveness of hepatic nitrogen metabolism to glucagon infusion in patients with cirrhosis: Dependence on liver cell failure. <i>Hepatology</i> , 1993, 18, 28-35.	7.3	18
369	Vegetable versus animal protein diet in cirrhotic patients with chronic encephalopathy. A randomized cross-over comparison. <i>Journal of Internal Medicine</i> , 1993, 233, 385-392.	6.0	137
370	Lactitol in treatment of chronic hepatic encephalopathy. <i>Digestive Diseases and Sciences</i> , 1993, 38, 916-922.	2.3	71
371	Thyroid involvement in chronic inflammatory rheumatological disorders. <i>Clinical Rheumatology</i> , 1993, 12, 479-484.	2.2	38
372	Hepatic conversion of amino nitrogen to urea nitrogen in hypothyroid patients and upon l-thyroxine therapy. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1263-1269.	3.4	20
373	Model-derived assessment of urea appearance in response to alanine infusion: A quantitative measure of liver function in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1993, 8, 550-556.	2.8	0
374	Prognostic significance of portal hemodynamics in patients with compensated cirrhosis. <i>Journal of Hepatology</i> , 1993, 17, 56-61.	3.7	90
375	Effect of S-adenosyl-L-methionine administration on plasma levels of sulphur-containing amino acids in patients with liver cirrhosis. <i>Clinical Nutrition</i> , 1992, 11, 303-308.	5.0	14
376	Polyamine plasma levels and liver regeneration following partial hepatic resection in man. <i>Journal of Hepatology</i> , 1992, 16, 159-164.	3.7	9
377	Defective methionine metabolism in cirrhosis: Relation to severity of liver disease. <i>Hepatology</i> , 1992, 16, 149-155.	7.3	59
378	Oral BCAA in the treatment of chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 1991, 12, 267.	3.7	6

#	ARTICLE	IF	CITATIONS
379	Elimination of infused branched-chain amino-acids from plasma of patients with non-obese type 2 diabetes mellitus. <i>Clinical Nutrition</i> , 1991, 10, 105-113.	5.0	11
380	Prognostic value of galactose elimination capacity, aminopyrine breath test, and ICG clearance in patients with cirrhosis. <i>Digestive Diseases and Sciences</i> , 1991, 36, 1197-1203.	2.3	86
381	Hepatic amino-nitrogen clearance to urea-nitrogen in control subjects and in patients with cirrhosis: A simplified method. <i>Hepatology</i> , 1991, 13, 460-466.	7.3	34
382	Intérêt de l'administration par voie orale d'acides aminés à chaîne ramifiée chez le cirrhotique encephalopathe chronique. <i>Nutrition Clinique Et Metabolisme</i> , 1991, 5, 207-214.	0.5	2
383	Thyroid gland size and function in patients with cirrhosis of the liver. <i>Liver</i> , 1991, 11, 71-77.	0.1	23
384	Glucose disposal, β -cell secretion, and hepatic insulin extraction in cirrhosis: A minimal model assessment. <i>Gastroenterology</i> , 1990, 99, 1715-1722.	1.3	71
385	Mathematical model to analyse urea synthesis following alanine infusion in control subjects and in patients with liver cirrhosis. <i>Medical and Biological Engineering and Computing</i> , 1990, 28, 325-328.	2.8	1
386	Ultrasonographic follow-up of liver cirrhosis. <i>Journal of Clinical Ultrasound</i> , 1990, 18, 91-96.	0.8	25
387	Synthesis of Urea after a Protein-rich Meal in Normal Man in Relation to Ageing. <i>Age and Ageing</i> , 1990, 19, 4-10.	1.6	20
388	Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 1990, 11, 92-101.	3.7	201
389	Analysis of the deterioration rates of liver function in cirrhosis, based on galactose elimination capacity. <i>Liver</i> , 1990, 10, 65-71.	0.1	19
390	Carbohydrate metabolism in hepatocellular carcinoma: Where does the glucose go?. <i>Hepatology</i> , 1989, 10, 253-255.	7.3	8
391	A rapid method for the <i>in vivo</i> measurement of liver volume. <i>Liver</i> , 1989, 9, 159-163.	0.1	28
392	Galactose elimination capacity and liver volume in aging man. <i>Hepatology</i> , 1988, 8, 1079-1083.	7.3	135
393	Caffeine intake, fasting plasma caffeine and caffeine clearance in patients with liver diseases. <i>Liver</i> , 1988, 8, 241-246.	0.1	9
394	Insulin resistance in aged man: Relationship between impaired glucose tolerance and decreased insulin activity on branched-chain amino acids. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 1096-1100.	3.4	17
395	Plasma clearances of branched-chain amino acids in control subjects and in patients with cirrhosis. <i>Journal of Hepatology</i> , 1987, 4, 108-117.	3.7	55
396	Insulin resistance is the main determinant of impaired glucose tolerance in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1987, 32, 1118-1124.	2.3	19

#	ARTICLE	IF	CITATIONS
397	Portal venous flow in response to acute β_2 -blocker and vasodilatory treatment in patients with liver cirrhosis. <i>Hepatology</i> , 1986, 6, 1248-1251.	7.3	77
398	Sonographic evaluation of liver, spleen, and splanchnic vessels following partial liver resection.. <i>Journal of Ultrasound in Medicine</i> , 1986, 5, 563-567.	1.7	3
399	Echo-doppler measurement of splanchnic blood flow in control and cirrhotic subjects. <i>Journal of Clinical Ultrasound</i> , 1986, 14, 429-435.	0.8	115
400	Evaluation of liver volume and liver function following hepatic resection in man. <i>Liver</i> , 1986, 6, 286-291.	0.1	37
401	Splanchnic vein measurements in patients with liver cirrhosis: a case-control study.. <i>Journal of Ultrasound in Medicine</i> , 1985, 4, 641-646.	1.7	30
402	Degeneration of the corticospinal tract following portosystemic shunt associated with spinal cord infarction. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1985, 406, 475-481.	1.4	19
403	Portal pressure changes induced by medical treatment: US detection.. <i>Radiology</i> , 1985, 155, 763-766.	7.3	14
404	Pancreatic β_2 -cell function in cirrhotic patients with and without overt diabetes. C-peptide response to glucagon and to meal. <i>Metabolism: Clinical and Experimental</i> , 1985, 34, 695-701.	3.4	24
405	The Euglycemic Clamp Technique in Patients with Liver Cirrhosis. <i>Hormone and Metabolic Research</i> , 1984, 16, 341-343.	1.5	22
406	Insulin-dependent metabolism of branched-chain amino acids in obesity. <i>Metabolism: Clinical and Experimental</i> , 1984, 33, 147-150.	3.4	49
407	Plasma amino acid response to protein ingestion in patients with liver cirrhosis. <i>Gastroenterology</i> , 1983, 85, 283-290.	1.3	34
408	Ammonia-induced changes in pancreatic hormones and plasma amino acids in patients with liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1982, 27, 406-412.	2.3	17
409	Muscle protein breakdown in uncontrolled diabetes as assessed by urinary 3-methylhistidine excretion. <i>Diabetologia</i> , 1982, 23, 456-8.	6.3	26
410	Branched-chain amino acids and alanine as indices of the metabolic control in Type 1 (insulin-dependent) and Type 2 (non-insulin-dependent) diabetic patients. <i>Diabetologia</i> , 1982, 22, 217-9.	6.3	40
411	Anticatabolic Effect of Branched-Chain Amino Acid-Enriched Solutions in Patients with Liver Cirrhosis. <i>Hepatology</i> , 1982, 2, 420S-425S.	7.3	87
412	Plasma Amino Acids as Markers of Liver Dysfunction in Cirrhotics. <i>Scandinavian Journal of Gastroenterology</i> , 1981, 16, 689-692.	1.5	11
413	Muscle protein breakdown in liver cirrhosis and the role of altered carbohydrate metabolism. <i>Hepatology</i> , 1981, 1, 294-299.	7.3	89
414	Prevalence of subclinical hepatic encephalopathy in cirrhotics and relationship to plasma amino acid imbalance. <i>Digestive Diseases and Sciences</i> , 1980, 25, 763-768.	2.3	61

#	ARTICLE	IF	CITATIONS
415	Insulin and glucagon levels in liver cirrhosis. Digestive Diseases and Sciences, 1979, 24, 594-601.	2.3	78
416	Nash As Part of the Metabolic (Insulin Resistance) Syndrome. , 0, , 55-65.		3
417	Lifestyle modification in the management of the metabolic syndrome: achievements and challenges. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 0, Volume 3, 373-385.	2.4	54